Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Last revision Both sides next revision
ad [2017/02/25 16:57]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
ad [2017/06/18 16:45]
sflitman [Alzheimer's Disease and Mild Cognitive Impairment]
Line 4: Line 4:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-| Mild Cognitive Impairment and Mild AD | Intravenous anti-amyloid antibody ​ |  II  |  Yes  |  25%  |  18 months ​ |  1+ years  | 
 | Mild Cognitive Impairment and Mild AD | Intravenous anti-amyloid antibody ​ |  III  |  Yes  |  33%  |  18 months ​ |  5 years  | | Mild Cognitive Impairment and Mild AD | Intravenous anti-amyloid antibody ​ |  III  |  Yes  |  33%  |  18 months ​ |  5 years  |
-| Early AD | Oral inhaled Cromolyn + Ibuprofen |  III  |  Yes  |  25%  |  72 weeks   ​| ​ None  | 
-| Mild AD | Oral RAGE antagonist |  III  |  Yes  |  50%  |  18 months ​ |  1+ years  | 
 | Mild AD | Oral BACE inhibitor |  III  |  Yes  |  50%  |  48 weeks  |  1+ years  | | Mild AD | Oral BACE inhibitor |  III  |  Yes  |  50%  |  48 weeks  |  1+ years  |
 +| Mild AD | Oral BACE inhibitor |  III  |  Yes  |  50%  |  48 weeks  |  1+ years  |
  
 Also see [[imaging|Imaging]]. Also see [[imaging|Imaging]].
Print/export
QR Code
QR Code ad (generated for current page)